Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications

Abstract

Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications

Author Biographies

V. М. Меretskyi, І. Gorbachevskyi Теrnopil National Medical University

Meretskyi Viktor M. MD, DSci(Med), Professor,
Professor of Pharmacology with Clinical Pharmacology Department
Ivan Horbachevsky Ternopil National Medical University, Ternopil
m.Voli, 1, Ternopil, 46001 Ukraine.
Phone: +380 352 524492
380 352 524492
meretskyy@tdmu.edu.ua
https://orcid.org/0000-0002-6358-6884

І. V. Меretska, І. Gorbachevskyi Теrnopil National Medical University

Meretska Iryna V., MD, PhD(Med)
Associate Professor of Clinical Pharmacy Department
Ivan Horbachevsky Ternopil National Medical University, Ternopil
m.Voli, 1, Ternopil, 46001 Ukraine.
Phone: +380 352 524492
380 352 524492
meretskaiv@tdmu.edu.ua
https://orcid.org/0000-0002-2953-903X

References

Vorob'jova NM, Panchenko EP. Antikoaguljantnaja terapija venoznyh trombojembolicheskih oslozhnenij: problemy i perspektivy. Rossijskij kardiologicheskij zhurnal. 2015;(3):7-17. doi.org/10.15829/1560-4071-2015-3-7-17. [In Russian].

Rudakova AV. Farmakojekonomicheskie aspekty primenenija apiksabana dlja profilaktiki serdechnososudistyh oslozhnenij u pacientov s neklapannoj fibrilljaciej predserdij. Racional'naja Farmakoterapija v Kardiologii. 2015;11(1):60-2. doi: 10.20996/1819-6446-2015-11-1-60-62. [In Russian].

Laguta PS. Venoznye trombozy: sovremennoe lechenie. Aterotromboz. 2015;(2):7-16. doi: 10.21518/2307-1109-2015-2-7-16. [In Russian].

Franchini M, Mannucci PM. Direct oral anticoagulants and venous thromboembolism. European Respiratory Review. 2016;(25):295-302. doi: 10.1183/16000617.0025-2016.

Rudakova AV. Farmakojekonomicheskie aspekty profilaktiki venoznyh trombojembolicheskih oslozhnenij pri jendoprotezirovanii krupnyh sustavov. Racional'naja Farmakoterapija v Kardiologii. 2015;11(3):287-92. doi: 10.20996/1819-6446-2015-11-3-287-292. [In Russian].

Jun M, Lix LM, Durand M, Dahl M, Paterson JM, Dormuth CR, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicenter, population based, observational study. BMJ. 2017;(359):j4323. doi: 10.1136/bmj.j4323.

Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, Batorova A, Boda Z, Christory F, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. Br J Anaesth. 2018;120(4):645-56. doi: 10.1016/j.bja.2017.11.082.

Skybchyk VA. Praktychni aspekty vykorystannia novoho peroralnoho antykoahulianta apiksabanu z metoiu profilaktyky insultu ta tromboembolii. Liky Ukrainy. 2016;1-2(197-198):15-9. [In Ukrainian].

Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015;35(5):1056-65. doi: 10.1161/ATVBAHA.115.303397.

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. doi: 10.1016/j.chest.2015.11.026.

Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363-71. doi: 10.1161/ATVBAHA.114.304488.

Lee LH. DOACs - advances and limitations in real world. Thromb J. 2016;14(Suppl 1):17. doi: 10.1186/s12959-016-0111-3.

Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee MJ. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. Am Heart Assoc. 2017;6(7). doi: 10.1161/JAHA.117.005835.

Cabral KP, Ansell JE. The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag. 2015;(11): 17-23. doi: 10.2147/VHRM.S39726.

Kunk PR, Brown J, McShane M, Palkimas S, Macik BG. Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis. 2017;(43):79-85. doi.org/10.1007/s11239-016-1420-x.

Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, et al. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019;(47):345-52. doi.org/10.1007/s11239-019-01823-y.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2009;(361):1139-51. doi: 10.1056/NEJMoa0905561.

Meretskyi V, Meretska I, Pertsovych V. Direct factor Xa inhibitor in the prevention of thromboembolism. Health Prob Civil. 2018;12(4):247-54. doi: 10.5114/hpc.2018.79987.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi: 10.1056/NEJMoa1302507.

Rago A, Papa AA, Cassese A, Arena G, Magliocca MCG, D’Onofrio A, et al. Clinical performance of apixaban vs. vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study. Am J Cardiovasc Drugs. 2019; 1-7. doi: 10.1007/s40256-019-00341-9.

Sikorska J, Uprichard J. Direct Oral Anticoagulants: A Quick Guide. European Cardiology Review. 2017;2(1):40-5. doi.org/10.15420/ecr.2017:11:2.

Vanden Daelen S, Peetermans M, Vanassche T, Verhamme P, Vandermeulen E. Monitoring and reversal strategies for new oral anticoagulants. Expert Rev Cardiovasc Ther. 2015 Jan;13(1):95-103. doi: 10.1586/14779072.2015.987126.

Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med. 2012 Dec;23(8):692-5. doi: 10.1016/j.ejim.2012.10.001.

Bel'diev SN. Prakticheskie aspekty primenenija apiksabana v klinicheskoj praktike: prodolzhenie temy. Racional'naja Farmakoterapija v Kardiologii. 2015;11(5):543-7. doi.org/10.20996/1819-6446-2015-11-5-543-547. [In Russian].

Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015;(54):651-62. doi: 10.1007/s40262-014-0228-0.

Schultz NH, Lundblad R, Holme PA. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series. Journal of Medical Case Reports. 2018;(12):138. doi: 10.1186/s13256-018-1660-9.

Keeling D, Tait RC, Watson H. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175(4):602-13. doi: 10.1111/bjh.14344.

Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016;4(11):870-80. doi: 10.1016/j.jchf.2016.07.012. 29. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150(6):1302-12. doi: 10.1016/j.chest.2016.07.013.

Shahmatova OO, Panchenko EP. Apiksaban v lechenii fibrilljacii predserdij: randomizirovannye issledovanija i povsednevnaja klinicheskaja praktika. Aterotromboz. 2017;(1):67-77. doi: 10.21518/2307-1109-2017-1-67-77. [In Russian].

Napalkov DA, Sokolova AA, Fomin VV. Dannye real'noj klinicheskoj praktiki kak instrument pri vybore prjamogo peroral'nogo antikoaguljanta. Racional'naja Farmakoterapija v Kardiologii. 2017;13(1):95-9. doi: 10.20996/1819-6446-2017-13-1-95-99. [In Russian].

Javelov IS. K voprosu o bezopasnosti prjamyh peroral''nyh antikoaguljantov: rezul''taty sopostavlenija apiksabana i varfarina. Aterotromboz. 2018;(2):54-67. doi: 10.21518/2307-1109-2018-2-54-67. [In Russian].

Giljarov MJu, Konstantinova EV. Peroral''nye antikoaguljanty v lechenii venoznyh trombo-jembolicheskih oslozhnenij: fokus na apiksaban. Medicinskij sovet. 2017;7:56-62. doi: 10.21518/2079-701X-2017-7-56-62. [In Russian].

Javelov IS. Peroral'nye antikoaguljanty prjamogo dejstvija v lechenii venoznyh trombojembolicheskih oslozhnenij: mesto apiksabana. Trudnyj pacient. 2015;13(10-11):18-23. [In Russian].

Krjukov AV, Sychev DA, Tereshhenko OV. Farmakogeneticheskie aspekty primenenija novyh oral'nyh antikoaguljantov. Racional'naja Farmakoterapija v Kardiologii. 2017;13(3):416-21. doi: 10.20996/1819-6446-2017-13-3-416-421. [In Russian].

Howe Z, Naville-Cook C, Cole D. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. J Thromb Thrombolysis. 2019;(47):280-6. doi: 10.1007/s11239-018-1770-7.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-98. doi: 10.1056/NEJMoa1006885.

Ando M, Inden Y, Yoshida Y, Sairaku A, Yanagisawa S, Suzuki H, et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels. 2019;1-9. doi: 10.1007/s00380-019-01370-9 06.

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi: 10.1093/europace/euv309.

Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, et al. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin К antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Services Research. 2017;17(1):74. doi: 10.1186/s12913-017-1995-8.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039.

Published
2019-06-27
How to Cite
МеretskyiV. М., & МеretskaІ. V. (2019). Application of a new peroral anticoagulants in treatment and prophylaxis of thromboembolic complications. Klinicheskaia Khirurgiia, 86(6), 73-76. https://doi.org/10.26779/2522-1396.2019.06.73